| Revista: | Anais brasileiros de dermatologia |
| Base de datos: | |
| Número de sistema: | 000558050 |
| ISSN: | 0365-0596 |
| Autors: | Miot, Hélio Amante1 Criado, Paulo Ricardo2 Castro, Caio César Silva de4 Ianhez, Mayra6 Talhari, Carolina7 Ramos, Paulo Müller1 |
| Institucions: | 1Universidade Estadual Paulista, Faculty of Medicine, Botucatu. Brasil 2Faculdade de Medicina do ABC, Centro Universitário, Santo André, São Paulo. Brasil 3Faculdade de Ciências Médicas de Santos, Santos, SP. Brasil 4Hospital de Dermatologia Sanitária do Paraná, Curitiba, PR. Brasil 5Pontifícia Universidade Católica do Paraná, Escola de Medicina, Curitiba, Paraná. Brasil 6Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás. Brasil 7Universidade do Estado do Amazonas, Department of Dermatology, Manaus, Amazonas. Brasil |
| Any: | 2023 |
| Volum: | 98 |
| Número: | 5 |
| Paginació: | 656-677 |
| País: | Brasil |
| Idioma: | Inglés |
| Resumen en inglés | The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice. |
| Keyword: | Alopecia areata, Atopic dermatitis, Janus Kinase Inhibitors, Psoriasis, Treatment, Vitiligo |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
